

# LiMAP-curvature: a simple model-free approach for analysing dose-finding studies

Linxi Han<sup>a</sup>, Qiqi Deng<sup>b</sup>, Zhangyi He<sup>c,1,\*</sup>, Feng Yu<sup>a,\*</sup>

<sup>a</sup>*School of Mathematics, University of Bristol, Bristol, UK*

<sup>b</sup>*Biostatistics, ModernaTX Inc, Cambridge, Connecticut, USA*

<sup>c</sup>*Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK*

---

## Abstract

MCP-Mod (Multiple Comparison Procedure-Modelling) is an efficient statistical method for the analysis of Phase II dose-finding trials, although it requires specialised expertise to pre-specify plausible candidate models along with model parameters. This can be problematic given limited knowledge of the agent/compound being studied, and misspecification of candidate models and model parameters can severely degrade its performance. To circumvent this challenge, in the work, we introduce LiMAP-curvature, a Bayesian model-free approach for the detection of the dose-response signal in Phase II dose-finding trials. LiMAP-curvature is built upon a Bayesian hierarchical framework incorporating information about the total curvature of the dose-response curve. Through extensive simulations, we show that LiMAP-curvature has comparable performance to MCP-Mod if the true underlying dose-response model is included in the candidate model set of MCP-Mod. Otherwise, LiMAP-curvature can achieve performance superior to that of MCP-Mod, especially when the true dose-response model drastically deviates from candidate models in MCP-Mod.

*Keywords:* Dose-finding trial, Dose-response signal detection, Model-free approach, Bayesian hierarchical model, Curvature prior

---

## 1. Introduction

Characterising the dose-response relationship and finding the right dose are important but challenging in the pharmaceutical drug development process. Nearly half of failures in Phase III trials result in part from a lack of understanding of the dose-response relationship in Phase II

---

\*Corresponding author.

*Email addresses:* [zhe1@georgeinstitute.org.uk](mailto:zhe1@georgeinstitute.org.uk) (Zhangyi He), [feng.yu@bristol.ac.uk](mailto:feng.yu@bristol.ac.uk) (Feng Yu)

<sup>1</sup>Present address: The George Institute for Global Health, Imperial College London, London W12 7RZ, UK

5 trials (Sacks et al., 2014). Over the last decade, the Multiple Comparison Procedure-Modelling  
6 (MCP-Mod) method, developed by Bretz et al. (2005), has been increasingly popular for Phase  
7 II trials as it can provide superior statistical evidence for dose selection.

8 MCP-Mod is a two-step approach that combines MCP principles and modelling techniques.  
9 In the first MCP step, it establishes a dose-response signal (Proof of Concept, PoC), and in the  
10 second Mod step, it estimates the dose-response curve and target doses of interest. MCP-Mod  
11 overcomes shortcomings of traditional approaches for dose-finding studies (see e.g. Ting, 2006,  
12 for an excellent introduction). MCP-Mod requires the pre-specification of plausible candidate  
13 models and model parameters to capture model uncertainty, which however is primarily based  
14 on the limited knowledge of the agent/compound being studied, if it is available at all (Chen  
15 & Liu, 2020). Misspecification of candidate models and model parameters in MCP-Mod may  
16 cause a loss in power and unreliable model selection (see Saha & Brannath, 2019, and references  
17 therein).

18 Motivated by the limitations of MCP-Mod, non-parametric methods have gained popularity  
19 for detecting dose-response trends and estimating dose-response relationships in Phase II trials.  
20 These methods offer flexibility and adaptability to capture complex patterns in the data with-  
21 out imposing strong assumptions on the underlying functional form of the dose-response curve.  
22 West & Harrison (2006) introduced the normal dynamic linear model (NDLM), which leverages  
23 the flexibility of dynamic linear models to estimate the dose-response curve. By accommodating  
24 time-varying coefficients, NDLM can capture the dynamic nature of the dose-response relation-  
25 ship, allowing for more accurate and interpretable estimates. Kirby et al. (2009) applied cubic  
26 smoothing splines with generalised cross-validation for the smoothing parameter to estimate  
27 the dose-response curve.

28 However, these approaches still face challenges in incorporating prior knowledge about the  
29 curvature or shape of the dose-response curve. Determining the optimal level of smoothness or  
30 choosing the appropriate model can be subjective and dependent on the specific data at hand.  
31 To address these limitations, in this work, we develop a model-free Bayesian approach, which is  
32 a novel Bayesian hierarchical framework incorporating the total (in the  $L^2$  sense) curvature of  
33 the dose-response curve as a prior parameter. Our approach avoids the requirement of a set of  
34 pre-specified candidate models. The responses at the given set of doses are estimated through

35 maximum *a posteriori* (MAP), with which we construct a test statistic to establish PoC through  
36 simulations. We can then estimate the dose-response relationship with simple interpolation.

37 The remainder of this work is organised as follows. We describe in detail our MAP approach  
38 with a curvature prior, abbreviated LiMAP-curvature, in Section 2. In Section 3, we evaluate the  
39 operating characteristics of LiMAP-curvature through simulations and compare its performance  
40 to that of MCP-Mod and smoothing spline. We present concluding remarks and future directions  
41 in Section 4.

## 42 2. Methods

43 We consider a trial with a total of  $M + 1$  distinct doses  $x_0, x_1, \dots, x_M$ , where  $x_0$  represents  
44 placebo. We let  $N_i$  be the number of patients in dose group  $i$  and  $f(x)$  be the true dose-response  
45 function at dose  $x$ . We assume that  $f(x)$  is defined on the interval  $[0, 1]$  to align with the typical  
46 range of doses in pharmaceutical drug development where doses are often scaled or normalised  
47 within this range for convenience and comparability. For  $i = 0, 1, \dots, M$  and  $j = 1, 2, \dots, N_i$ ,  
48 we let  $Y_{ij}$  be the response observed for patient  $j$  allocated to dose  $x_i$ . We assume that

$$Y_{ij} = \mu_i + \epsilon_{ij}, \tag{1}$$

49 where  $\mu_i = f(x_i)$  denotes the mean response at dose  $x_i$ , and  $\epsilon_{ij} \stackrel{iid}{\sim} N(0, \sigma^2)$  denotes the error  
50 term for patient  $j$  in dose group  $i$ . For the sake of simplicity, we assume that the variance  $\sigma^2$  is  
51 known and constant across all dose groups. This assumption is commonly used in different areas,  
52 including MCP-Mod (Bretz et al., 2005), BMCPMod (Fleischer et al., 2022) and Bayesian meta-  
53 analysis (Burke et al., 2018). See Fleischer et al. (2022) for further discussion on the assumption  
54 on the standard deviation  $\sigma$ .

55 In MCP-Mod, a set of plausible candidate models is required. This constrains the possible  
56 set of dose-response curves. However, with limited knowledge of the agent/compounds in Phase  
57 II trials, it is more likely to mis-specify the set of candidate models. The procedure for specifying  
58 candidate models is also somewhat cumbersome. So we would like to avoid the pre-specification  
59 of possible models beforehand, but still want to impose a certain degree of smoothness on the

60 dose-response curve. To this end, we introduce the  $L^2$ -total curvature

$$Sf = \left( \int_{x_0}^{x_M} f''(x)^2 dx \right)^{1/2}$$

61 to measure how far the dose-response curve  $f(x)$  is from being a straight line. We will impose a  
 62 half-normal  $HN(\gamma^2)$  prior on  $Sf$  to give low prior probabilities to the dose-response relationship  
 63 that is very curved, where the standard deviation  $\gamma$  controls the trade-off between the  $L^2$ -total  
 64 curvature of  $f(x)$  and fidelity to data  $\mathbf{Y}$ . To capture an appropriate level of curvature and allow  
 65 for optimal model performance, we assign a hyperprior for  $\gamma$  with a half-normal distribution  
 66  $HN(\tau^2)$ , which reflects our prior beliefs about the likely range of values for  $\gamma$  before observing  
 67 any data. By incorporating a hyperprior, we introduce additional uncertainty and flexibility  
 68 into the prior distribution of  $Sf$ , influencing the estimation of the dose-response curve. The  
 69 specification of the standard deviation  $\tau$  will be discussed in Section 4.

70 Given the dose-response function  $f(x)$  being available at  $M + 1$  distinct doses, for  $i =$   
 71  $1, 2, \dots, M - 1$ , we have

$$f''(x_i) \approx 2 \left( \frac{\mu_{i+1} - \mu_i}{(x_{i+1} - x_i)(x_{i+1} - x_{i-1})} - \frac{\mu_i - \mu_{i-1}}{(x_i - x_{i-1})(x_{i+1} - x_{i-1})} \right)$$

72 through the second-order central difference scheme (Burden et al., 2015), therefore the  $L^2$ -total  
 73 curvature  $Sf$  being approximated through numerical integration with

$$S_\mu = 2 \left( \sum_{i=1}^{M-1} \left( \frac{\mu_{i+1} - \mu_i}{(x_{i+1} - x_i)(x_{i+1} - x_{i-1})} - \frac{\mu_i - \mu_{i-1}}{(x_i - x_{i-1})(x_{i+1} - x_{i-1})} \right)^2 \Delta x_i \right)^{1/2},$$

74 where  $\Delta x_i = (x_{i+1} - x_{i-1})/2$  for  $i = 2, 3, \dots, M - 2$  with  $\Delta x_1 = (x_2 + x_1)/2 - x_0$  and  $\Delta x_{M-1} =$   
 75  $x_M - (x_{M-1} + x_{M-2})/2$ .

76 We let

$$\mathbf{Y} = \{Y_{ij}, i = 0, 1, \dots, M, j = 1, 2, \dots, N_i\}$$

77 and define our Bayesian hierarchical model to be

$$p(\boldsymbol{\mu}, \gamma \mid \mathbf{Y}) \propto p(\boldsymbol{\mu}, \gamma) p(\mathbf{Y} \mid \boldsymbol{\mu}), \quad (2)$$

78 where the prior

$$p(\boldsymbol{\mu}, \gamma) = p(\gamma) \prod_{i=0}^M p(\mu_i) p(S_{\boldsymbol{\mu}} | \gamma)$$

79 with

$$S_{\boldsymbol{\mu}} | \gamma \sim HN(\gamma^2), \quad \gamma \sim HN(\tau^2), \quad \mu_i \stackrel{iid}{\sim} U(0, 1) \text{ for } i = 0, 1, \dots, M,$$

80 and the likelihood

$$p(\mathbf{Y} | \boldsymbol{\mu}) = \prod_{i=0}^M \prod_{j=1}^{N_i} p(Y_{ij} | \mu_i).$$

81 Suppose the standard deviation  $\tau$  in the hyperprior for  $\gamma$  is pre-specified. The MAP estimates of  
 82 all parameters in the model defined in Eq. (2) can be obtained by maximising the corresponding  
 83 log-likelihood

$$\begin{aligned} \hat{\boldsymbol{\mu}}, \hat{\gamma} &= \arg \max_{\boldsymbol{\mu}, \gamma} \log p(\boldsymbol{\mu}, \gamma | \mathbf{Y}) \\ &\propto \arg \max_{\boldsymbol{\mu}, \gamma} \left\{ - \sum_{i=0}^M \sum_{j=1}^{N_i} \left( \frac{Y_{ij} - \mu_i}{\sigma} \right)^2 - 2 \log \gamma - \left( \frac{S_{\boldsymbol{\mu}}}{\gamma} \right)^2 - \left( \frac{\gamma}{\tau} \right)^2 \right\} \end{aligned}$$

84 through a numerical optimisation algorithm like the Broyden–Fletcher–Goldfarb–Shanno (BFGS)  
 85 method and its variants (see, e.g. Nocedal & Wright, 1999, for more details).

86 To establish PoC, we propose a test statistic

$$T = \max\{\mu_1 - \mu_0, \mu_2 - \mu_0, \dots, \mu_M - \mu_0\}$$

87 with hypotheses

$$H_0 : \mu_1 = \dots = \mu_M = \mu_0$$

$$H_1 : \max\{\mu_1, \mu_2, \dots, \mu_M\} > \mu_0.$$

88 We define a significance level  $\alpha$  for a dose-response signal, such that the corresponding critical  
 89 value  $c$  satisfies

$$\mathbb{P}(T > c | H_0) < \alpha.$$

90 For a given  $\alpha$ , we compute the critical value  $c$  via simulation

$$\mathbb{P}(T > c \mid H_0) \approx \frac{1}{R} \sum_{r=1}^R \mathbb{1}_{\{T^{(r)} > c\}},$$

91 where  $T^{(r)}$  is the test statistic computed from the data  $\mathbf{Y}^{(r)}$  simulated under the null hypothesis  
92  $H_0$ ,  $R$  is the total number of replicates, and  $\mathbb{1}_A$  is the indicator function equal to 1 if condition  
93  $A$  holds and 0 otherwise.

94 Finally, the mean response estimates  $\hat{\boldsymbol{\mu}}$  can be linearly interpolated (or using a more sophis-  
95 ticated interpolation scheme) to obtain an estimate of the dose-response curve  $f(x)$ , which will  
96 also yield an estimate of the target dose of interest. In this work, we only perform simple linear  
97 interpolation as we shall focus on the PoC stage of dose-finding trials.

### 98 3. Simulations

99 In this section, we assess the performance of LiMAP-curvature, in terms of power to detect  
100 dose-response signals as well as estimates of the dose-response curve and target doses of interest.  
101 We compare LiMAP-curvature to smoothing spline and MCP-Mod.

#### 102 3.1. Simulation settings

103 We simulate randomised, double-blind, placebo-controlled, parallel-group trials with pa-  
104 tients being equally allocated to placebo (0) or one of four active doses (0.15, 0.50, 0.80 and 1).  
105 We take the placebo effect to be 0 and the maximum treatment effect to be 0.5, respectively.  
106 We vary the sample size per dose group in  $\{10, 20, 30, 40, 50, 60\}$ . We choose one of 12 common  
107 dose-response shapes to be the true dose-response model. These models are plotted in Figure 1,  
108 with corresponding parameters summarised in Supplemental Material, Table S1. We simulate  
109 each patient's response according to Eq. (1) with a standard deviation of  $\sigma = 1$ . For each of 72  
110 combinations of parameters, consisting of sample size and dose-response shape, we run 10,000  
111 simulated trials.

112 For each simulated trial, we run LiMAP-curvature to establish PoC and find the target doses  
113 of interest with a standard deviation of  $\tau \in \{1, 3, 5\}$  for the hyperprior  $HN(\tau^2)$ . To benchmark  
114 LiMAP-curvature against smoothing spline and MCP-Mod, we run smoothing spline through  
115 the **stats** package (version 3.6.2) in R and employ the generalised cross-validation to choose the




Figure 1: Dose-response shapes selected for the true dose-response model.

116 smoothing parameter for smoothing spline (Green & Silverman, 1993). We also run MCP-Mod  
117 through the **DoseFinding** package (version 1.0-4) in R, where we specify a fixed set of candidate  
118 models made up of linear, emax1, emax2, exponential1, quadratic and logistic1 (top six figures  
119 of Figure 1).

### 120 3.2. Simulation results

121 To evaluate the performance of LiMAP-curvature, smoothing spline and MCP-Mod, we plot  
122 receiver operating characteristic (ROC) curves for all true dose-response models for sample size  
123 40 in Figure 2. The ROC curve is produced by plotting the true positive rate against the false  
124 positive rate across a range of critical values. The closer the ROC curve approaches the top left  
125 corner, the better the method performs overall. See Supplemental Material, Figures S1-S5 for  
126 ROC curves for all other sample sizes. We also summarise their powers at 5% and 10% type I  
127 error rates in Supplemental Material, Table S2 and S3, respectively.

128 As illustrated in Figure 2, we find that LiMAP-curvature has better performance when the  
129 true dose-response relationship is not dramatically curved, e.g. linear, emax1, logistic1, logistic2  
130 and sigEmax, achieving over 80% power at a type I error rate of 5%. Choosing an appropriate  $\tau$   
131 can further improve the performance of LiMAP-curvature. More specifically, LiMAP-curvature  
132 achieves better performance with a larger  $\tau$  for the true dose-response curve that is more curved,  
133 e.g. quadratic1 and beta models. Otherwise, e.g. in logistic1 and power models, a smaller  $\tau$   
134 performs better. How to select an appropriate  $\tau$  in practice will be discussed in Section 4.

135 To benchmark the performance of LiMAP-curvature, smoothing spline and MCP-Mod, we  
136 consider two cases:

- 137 1. the true dose-response curve is one of the candidate models in MCP-Mod,
- 138 2. the true dose-response curve is not one of the candidate models in MCP-Mod.

139 Figures 2(a-f) compare the performance of LiMAP-curvature, smoothing spline and MCP-Mod  
140 for the first case, which is a fairly rare situation in practice. The resulting ROC curves are in  
141 favour of MCP-Mod as expected due to its utilisation of exact population parameter estimates  
142 in its candidate model set, but LiMAP-curvature with  $\tau = 3$  achieves comparable performance.  
143 We note that for the true dose-response curve that is not dramatically curved, e.g. linear, emax1  
144 and logistic1,  $\tau = 1$  yields better performance than when  $\tau = 3$ , resulting in a power gain of  
145 around 2-9% compared to MCP-Mod and around 8-11% compared to smoothing spline, all at  
146 5% type I error rate.

147 Figures 2(g-l) compare the performance of LiMAP-curvature, smoothing spline and MCP-  
148 Mod for the second case. This is the situation we expect to encounter in practice. We see that  
149 with  $\tau = 3$ , LiMAP-curvature uniformly outperforms MCP-Mod, especially when the true dose-






Figure 2: ROC curves of LiMAP-curvature, smoothing spline and MCP-Mod across different true dose-response models with the sample size of 40 patients per arm. The ROC curves of MCP-Mod in (a)-(f) are produced with the true dose-response model not included in the candidate model set, and the ROC curves of MCP-Mod in (g)-(l) are produced with the true dose-response model not included in the candidate model set.

150 response model drastically deviates from the candidate model set in MCP-Mod such as sigEmax  
 151 and beta models. In the latter case, LiMAP-curvature has a power gain of approximately 5-13%  
 152 compared to MCP-Mod at a type I error rate of 5%. Some true dose-response models such as  
 153 exponential2, quadratic2 and power models, are well captured by the candidate model set of  
 154 MCP-Mod so that we see the similar performance of LiMAP-curvature and MCP-Mod. Even

155 with an inappropriate choice of  $\tau$ , LiMAP-curvature is still able to achieve significantly better  
156 performance, e.g. a power gained by approximately 2-3% over MCP-Mod at a 5% type I error  
157 rate. Moreover, compared to the smoothing spline, LiMAP-curvature consistently outperforms  
158 it, except for the beta model. LiMAP-curvature demonstrates a power gain of about 3-9% over  
159 smoothing spline at a 5% type I error rate.

160 We also evaluate and compare the performance in estimating the dose-response curve and  
161 target doses of interest, known as the minimum effective dose (MED). See Supplemental Mate-  
162 rial, Figures S6-S11 for the dose-response curves estimated using LiMAP-curvature, smoothing  
163 spline and MCP-Mod for various true dose-response models and sample sizes. The correspond-  
164 ing results for MED estimation are summarised in Supplemental Material, Table S4.

#### 165 4. Discussion

166 In this work, we have introduced LiMAP-curvature, a novel Bayesian approach for establish-  
167 ing PoC and estimating the dose-response curve alongside target doses of interest in Phase II  
168 trials. LiMAP-curvature is “model-free”, in the sense that it does not require pre-specification of  
169 candidate dose-response models, which can influence the performance of MCP-Mod. It is built  
170 on a Bayesian hierarchical framework incorporating prior information on the  $L^2$ -total curvature  
171 of the dose-response curve.

172 We have shown through simulations that LiMAP-curvature has performance comparable to  
173 that of MCP-Mod in establishing PoC and estimating MED when the true dose-response model  
174 is included in the candidate model set of MCP-Mod, which is fairly rare in practice. When the  
175 true dose-response model deviates from the candidate model set of MCP-Mod, LiMAP-curvature  
176 has been demonstrated to outperform MCP-Mod. Furthermore, we note that LiMAP-curvature  
177 also outperforms smoothing spline in terms of power to detect dose-response signals in most  
178 cases. This indicates the advantages of LiMAP-curvature over the widely used non-parametric  
179 method of smoothing spline. The ability of LiMAP-curvature to consistently outperform both  
180 MCP-Mod and smoothing spline across various scenarios highlights its effectiveness and poten-  
181 tial as a valuable tool in Phase II trial analysis.

182 To obtain optimal performance, MCP-Mod requires specialised expertise to pre-specify plau-  
183 sible candidate models and model parameters, but the knowledge of the agent/compounds being  
184 studied is usually limited. Compared to MCP-Mod, the only requirement for pre-specification

185 in LiMAP-curvature is the standard deviation  $\tau$  for the hyperprior  $\gamma \sim HN(\tau^2)$ , which encodes  
186 prior knowledge of how far the dose-response curve is from a straight line. With additional sim-  
187 ulations with varying values of the standard deviation  $\tau$  (see Supplemental Material, Figure S12  
188 and Table S5), we recommend choosing

- 189 1.  $\tau \in [2, 4]$  if our prior knowledge is poor,
- 190 2.  $\tau < 2$  if we are confident that the curvature of the dose-response curve is weak,
- 191 3.  $\tau > 4$  if we are confident that the curvature of the dose-response curve is strong.

192 A number of relevant issues for LiMAP-curvature deserve further research. One such exten-  
193 sion involves integrating the sigmoid Emax model as the default response function within the  
194 LiMAP-curvature framework. The sigmoid Emax model is noted for its ability to approximate  
195 most common monotonic dose-response relationships, providing a robust framework for mod-  
196 elling complex dose-response relationships. However, the challenge lies in selecting appropriate  
197 prior distributions for the additional parameters introduced by the sigmoid Emax model, which  
198 requires careful consideration to ensure accurate and reliable dose-response estimation. Another  
199 important extension involves adapting LiMAP-curvature to handle a wider variety of endpoints  
200 and trial designs. The current version of LiMAP-curvature is limited to the analysis Phase II  
201 dose-finding trials with continuous endpoints, i.e. a single normally distributed homoscedastic  
202 response measured at the end of the trial. To expand its applicability, extensions to other com-  
203 mon types of endpoints (e.g. binary, counts and survival endpoints) and trials (e.g. longitudinal  
204 dose-finding trials) require further investigation. Other directions of future research include the  
205 investigation of trial designs tailored to LiMAP-curvature and the development of statistical  
206 software implementing LiMAP-curvature.

## 207 **Disclosure Statement**

208 The authors report there are no competing interests to declare.

## 209 **Disclaimer**

210 The opinions expressed in this paper are solely those of the authors and not those of their  
211 affiliations. The authors' affiliations do not guarantee the accuracy or reliability of the infor-  
212 mation provided herein.

## 213 References

- 214 Bretz, F., Pinheiro, J. C., & Branson, M. (2005). Combining multiple comparisons and modeling  
215 techniques in dose-response studies. *Biometrics*, *61*, 738–748.
- 216 Burden, R. L., Faires, J. D., & Burden, A. M. (2015). *Numerical Analysis*. Boston: Cengage  
217 Learning.
- 218 Burke, D. L., Bujkiewicz, S., & Riley, R. D. (2018). Bayesian bivariate meta-analysis of corre-  
219 lated effects: Impact of the prior distributions on the between-study correlation, borrowing  
220 of strength, and joint inferences. *Statistical Methods in Medical Research*, *27*, 428–450.
- 221 Chen, J., & Liu, T. (2020). Statistical considerations on implementing the MCP-Mod method  
222 for binary endpoints in clinical trials. *Contemporary Clinical Trials Communications*, *19*,  
223 100641.
- 224 Fleischer, F., Bossert, S., Deng, Q., Loley, C., & Gierse, J. (2022). Bayesian MCPMod. *Phar-*  
225 *maceutical Statistics*, *21*, 654–670.
- 226 Green, P. J., & Silverman, B. W. (1993). *Nonparametric Regression and Generalized Linear*  
227 *Models: A roughness penalty approach*. London: CRC Press.
- 228 Kirby, S., Colman, P., & Morris, M. (2009). Adaptive modelling of dose-response relationships  
229 using smoothing splines. *Pharmaceutical Statistics*, *8*, 346–355.
- 230 Nocedal, J., & Wright, S. J. (1999). *Numerical Optimization*. New York: Springer.
- 231 Sacks, L. V., Shamsuddin, H. H., Yasinskaya, Y. I., Bouri, K., Lanthier, M. L. et al. (2014).  
232 Scientific and regulatory reasons for delay and denial of FDA approval of initial applications  
233 for new drugs, 2000-2012. *JAMA*, *311*, 378–384.
- 234 Saha, S., & Brannath, W. (2019). Comparison of different approaches for dose response analysis.  
235 *Biometrical Journal*, *61*, 83–100.
- 236 Ting, N. (2006). *Dose Finding in Drug Development*. New York: Springer.
- 237 West, M., & Harrison, J. (2006). *Bayesian Forecasting and Dynamic Models*. New York:  
238 Springer.